COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

19/09/2024 - 14:00

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFF Placebo-adjusted median relative reductions in liver fat were up to 46.2% with a [...]

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

19/09/2024 - 14:00

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to [...]

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

19/09/2024 - 14:00

ZORYVE ® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerability Across both studies, approximately 31% of children and adults [...]

Aeroflow Health Launches Venture Arm; Co-Leads $3.7 Million Seed Round for Canopie

19/09/2024 - 14:00

ASHEVILLE, N.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services, today announced the [...]

HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health

19/09/2024 - 14:00

NAPLES, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. ( OTCQB: HLYK ), a leader in healthcare technology, is proud to announce its integration with Lyric Health, a comprehensive virtual care [...]

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

19/09/2024 - 14:00

- New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies support the potential of the BVP to deliver insulin-producing islets as a potential treatment for type [...]

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

19/09/2024 - 14:00

Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no severe adverse events or [...]

CorMedix Inc. Announces New Commercial Agreement

19/09/2024 - 14:00

BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today [...]

LifeMD Announces Major Enhancements to its Weight Management Program, Expanding Patient Access to Branded GLP-1 Therapies and Introducing New Treatment Options

19/09/2024 - 14:00

Investments in pharmacy benefits infrastructure, in-home lab services and new treatment options expand platform capabilities and are estimated to increase LifeMD’s addressable weight loss market by 15% NEW YORK, Sept. [...]

NewVue Announces Strategic Partner Agreement with Konica Minolta Healthcare to Enhance Radiology Workflow

19/09/2024 - 14:00

TAMPA, Fla. and WAYNE, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NewVue, a leader in cloud-native radiology workflow solutions, and Konica Minolta Healthcare Americas, Inc., a leading provider of medical diagnostic [...]

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

19/09/2024 - 13:30

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" [...]

Shock Top Announces its Official Craft Beer Sponsorship of University of Missouri Athletics

19/09/2024 - 13:12

PORTLAND, Ore., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Today, The Shock Top Company, a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), proudly announces a new partnership with Mizzou Athletics as the [...]

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational

19/09/2024 - 13:00

Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for Fill/Finish of Latest [...]

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

19/09/2024 - 13:00

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

19/09/2024 - 13:00

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

19/09/2024 - 13:00

New patent expected to expire in 2030 Tosymra ® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix [...]

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

19/09/2024 - 13:00

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for agitation associated [...]

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

19/09/2024 - 13:00

LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, [...]

Achilles Therapeutics Announces Strategic Update

19/09/2024 - 13:00

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE [...]